Role of the VEGFR3/VEGFD receptor axis in TGFβ1 activation of primary prostate cell lines

The Prostate ◽  
2009 ◽  
Vol 69 (9) ◽  
pp. 982-990 ◽  
Author(s):  
S.M. Goodyear ◽  
S.B. Kheyfets ◽  
F.U. Garcia ◽  
M.E. Stearns
Keyword(s):  
Cell Lines ◽  
Prostate Cell ◽  
Prostate Cell Lines

Modulation of YY1 and p53 expression by transforming growth factor-β3 in prostate cell lines

Cytokine ◽  
2011 ◽  
Vol 56 (2) ◽  
pp. 403-410 ◽  
Author(s):  
Silvia Caggia ◽  
Massimo Libra ◽  
Grazia Malaponte ◽  
Venera Cardile
Keyword(s):  
Growth Factor ◽  
Cell Lines ◽  
Transforming Growth Factor ◽  
Prostate Cell ◽  
P53 Expression ◽  
Prostate Cell Lines

scholarly journals Functional analyses of C13orf19/P38IP in prostate cell lines

2006 ◽  
Author(s):  
Doreen Kunze ◽  
Susanne Fuessel ◽  
Axel Meye ◽  
Manfred Wirth ◽  
Uta Schmidt
Keyword(s):  
Cell Lines ◽  
Prostate Cell ◽  
Functional Analyses ◽  
Prostate Cell Lines

scholarly journals Gene expression analysis of human prostate cell lines with and without tumor metastasis suppressor CD82

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Pushpaja Dodla ◽  
Vanitha Bhoopalan ◽  
Sok Kean Khoo ◽  
Cindy Miranti ◽  
Suganthi Sridhar
Keyword(s):  
Gene Expression ◽  
Cell Line ◽  
Cell Lines ◽  
Differentially Expressed Genes ◽  
Tumor Metastasis ◽  
Human Prostate ◽  
Metastasis Suppressor ◽  
Data Sets ◽  
Prostate Cell ◽  
Prostate Cell Lines

Abstract Background Tetraspanin CD82 is a tumor metastasis suppressor that is known to down regulate in various metastatic cancers. However, the exact mechanism by which CD82 prevents cancer metastasis is unclear. This study aims to identify genes that are regulated by CD82 in human prostate cell lines. Methods We used whole human genome microarray to obtain gene expression profiles in a normal prostate epithelial cell line that expressed CD82 (PrEC-31) and a metastatic prostate cell line that does not express CD82 (PC3). Then, siRNA silencing was used to knock down CD82 expression in PrEC-31 while CD82 was re-expressed in PC3 to acquire differentially-expressed genes in the respective cell line. Results Differentially-expressed genes with a P < 0.05 were identified in 3 data sets: PrEC-31 (+CD82) vs PrEC-31(−CD82), PC3–57 (+CD82) vs. PC3-5 V (−CD82), and PC3–29 (+CD82) vs. PC3-5 V (−CD82). Top 25 gene lists did not show overlap within the data sets, except (CALB1) the calcium binding protein calbindin 1 which was significantly up-regulated (2.8 log fold change) in PrEC-31 and PC3–29 cells that expressed CD82. Other most significantly up-regulated genes included serine peptidase inhibitor kazal type 1 (SPINK1) and polypeptide N-acetyl galactosaminyl transferase 14 (GALNT14) and most down-regulated genes included C-X-C motif chemokine ligand 14 (CXCL14), urotensin 2 (UTS2D), and fibroblast growth factor 13 (FGF13). Pathways related with cell proliferation and angiogenesis, migration and invasion, cell death, cell cycle, signal transduction, and metabolism were highly enriched in cells that lack CD82 expression. Expression of two mutually inclusive genes in top 100 gene lists of all data sets, runt-related transcription factor (RUNX3) and trefoil factor 3 (TFF3), could be validated with qRT-PCR. Conclusion Identification of genes and pathways regulated by CD82 in this study may provide additional insights into the role that CD82 plays in prostate tumor progression and metastasis, as well as identify potential targets for therapeutic intervention.

Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma

The Prostate ◽  
2002 ◽  
Vol 52 (4) ◽  
pp. 253-263 ◽  
Author(s):  
Shona H. Lang ◽  
Catherine Hyde ◽  
Ian N. Reid ◽  
Ian S. Hitchcock ◽  
Claire A. Hart ◽  
...  
Keyword(s):  
Cell Lines ◽  
Prostate Carcinoma ◽  
Prostate Cell ◽  
Enhanced Expression ◽  
Poorly Differentiated ◽  
Metastatic Prostate Carcinoma ◽  
Prostate Cell Lines
Sign in / Sign up

Export Citation Format

Share Document